Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prometheus Biosciences, Inc. - Common Stock (NQ: RXDX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prometheus Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?
Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials. 
Via InvestorPlace
Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease
Prometheus Biosciences made waves Wednesday in irritable bowel disease. 
Via Investor's Business Daily
These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday
Even as broader markets fell, these companies announced great news. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Prometheus Biosciences Stock Skyrockets After Favorable Data From Ulcerative Colitis, Crohn's Disease Studies
Via Benzinga
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
From Prometheus Biosciences
Via GlobeNewswire
Why Shares of Prometheus Biosciences Slumped This Week
The company's lead pipeline candidate is facing competition from a Pfizer-backed drug. 
Via The Motley Fool
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences to Participate at November Healthcare Conferences
From Prometheus Biosciences
Via GlobeNewswire
Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here's What You Need To Know
Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00. Shares of Prometheus Biosciences are trading down... 
Via Benzinga
Where Prometheus Biosciences Stands With Analysts
Over the past 3 months, 7 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Expert Ratings for Prometheus Biosciences
Within the last quarter, Prometheus Biosciences (NASDAQ:RXDX) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Prometheus Biosciences
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: 
Via Benzinga
Analyst Ratings for Prometheus Biosciences
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: 
Via Benzinga
Delta Air Lines To Rally Around 84%? Here Are 5 Other Price Target Changes For Tuesday
Raymond James raised Delta Air Lines, Inc. (NYSE: DAL) price target from $50 to $52. Raymond James analyst Savanthi Syth maintained a Strong Buy rating on the stock. Delta Air shares rose 0.7% to close... 
Via Benzinga
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
From Prometheus Biosciences
Via GlobeNewswire
7 Top-Rated Biotech Stocks to Buy for Q4
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers
Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. 
Via Benzinga
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to... 
Via Benzinga
Where Prometheus Biosciences Stands With Analysts
  Over the past 3 months, 4 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Prometheus Biosciences Stock Shows Rising Relative Strength
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
Via Benzinga
10 Biggest Price Target Changes For Thursday
Keybanc cut the price target on Asana, Inc. (NYSE: ASAN) from $97 to $61. Asana shares fell 23.6% to $37.29 in pre-market trading. 
Via Benzinga
Analyst Ratings For Prometheus Biosciences
Analysts have provided the following ratings for Prometheus Biosciences (NASDAQ:RXDX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Expert Ratings For Prometheus Biosciences
Over the past 3 months, 6 analysts have published their opinion on Prometheus Biosciences (NASDAQ:RXDX) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
52 Biggest Movers From Friday
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021
Upgrades According to B of A Securities, the prior rating for Globus Medical Inc (NYSE: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.